INTRODUCTION
Drug binding in G protein-coupled receptors (GPCRs) initiates signaling across cell membranes over a distance of $30 Å (Audet and Bouvier, 2012; Rosenbaum et al., 2009) . From the molecular architecture of GPCRs, as determined by X-ray crystallography, it is clear that this signal transfer must be supported by dynamic plasticity of the receptors, which needs to be investigated by other methods. Nuclear magnetic resonance (NMR) spectroscopy in solution complements GPCR crystal structure determination by its unique ability to detect multiple, simultaneously populated conformational states, as has been reported, for example, in studies of the b 2 -adrenergic receptor (b 2 AR) (Bokoch et al., 2010; Eddy et al., 2016; Horst et al., 2013; Kim et al., 2013; Kofuku et al., 2012 Kofuku et al., , 2014 Liu et al., 2012a; Manglik et al., 2015; Nygaard et al., 2013) , the m-opioid receptor (MOR) (Okude et al., 2015; Sounier et al., 2015) , the b 1 -adrenergic receptor (Isogai et al., 2016) , and the human A 2A adenosine receptor (A 2A AR) (Ye et al., 2016) . Thereby, drugs bound in the orthosteric pocket can alter the relative populations of two or multiple locally different conformational states on the intracellular surface, which signal to partner proteins (Didenko et al., 2013; Manglik and Kobilka, 2014) . Here, these potentialities of NMR in solution were used to investigate the structural basis of the functional role of Asp52 2.50 (superscripts indicate the Ballesteros-Weinstein nomenclature) (Ballesteros and Weinstein, 1995) , which has been reported to be a key residue in an allosteric switch along the 30-Å signaling pathway from the drug binding pocket of A 2A AR to its intracellular surface ( Figure 1A) .
The key role of Asp52 2.50 in regulating signaling to intracellular partner proteins has been experimentally documented for over 30 different class A GPCRs . Asp52 2.50 is also one of the most highly conserved residues, with aspartic acid at this position in $85% of the $700 class A GPCRs in the human proteome ( Figure 1B ) . For some GPCRs, replacement of Asp52 2.50 with an uncharged amino acid resulted in marked decrease of G protein signaling; examples include the cannabinoid receptors CB1 and CB2 (Tao and Abood, 1998) and the type 1 neurotensin receptor (NTSR1) (Martin et al., 1999) . For other receptors, including the angiotensin II receptor (Bihoreau et al., 1993) , MOR (Xu et al., 1999) and A 2A AR (Massink et al., 2015) , replacement of Asp52 2.50 has been reported to completely abolish G protein signaling. In addition to its role in regulating G protein signaling, Asp52 2.50 was seen in high-resolution crystal structures of A 2A AR and DOR to form coordinative bonds with a sodium ion (Liu et al., 2012b) , which provided an initial rationale for independently observed physiological effects of sodium ions on opiate ligand binding and receptor signaling (Cooper et al., 1982; Pert et al., 2009) . A 2A AR belongs to the purinergic receptor family that binds endogenous adenosine and regulates vasodilation and inflammation (Ohta and Sitkovsky, 2001 ) and affects the CNS (Dunwiddie and Masino, 2001) . A 2A AR is a validated target for the treatment of Parkinson's disease (Bara-Jimenez et al., 2003) , and more recently, it has been identified as a potential therapeutic target for cancer immunotherapies (Young et al., 2016) . A GPCRs: Asp 84%, Glu 10%, Arg and others 6% (Munk et al., 2016) .
(C) Ribbon representation of the crystal structure of the antagonist ZM241385 (green) complex of A 2A AR expressed in Pichia pastoris (PDB: 6AQF). The location of the fusion protein BRIL in the intracellular loop 3 (ICL3), where Gly218 was eliminated in the fusion protein, is indicated by a thin broken line; Gly218 was left intact in the A 2A AR sequence used for NMR studies (see Figure S1 for the location of Gly218 at the intracellular tip of trans-membrane helix VI in a structure without fusion protein). NMR-assigned tryptophan residues and their sequence positions are highlighted in blue, assigned glycine residues are orange, and the residue Asp52 2.50 is shown in red.
( See also Figures S2, S3, S4, S5, and S6 and  Tables S2 and S3. Relating to this biomedical interest, A 2A AR has been subject to intense studies, including crystal structure determinations of complexes with antagonists (Doré et al., 2011; Jaakola et al., 2008) and agonists (Lebon et al., 2011; Xu et al., 2011) and for a ternary complex of A 2A AR with an agonist and a ''mini-G S '' G protein mimetic (Carpenter et al., 2016) . A recent crystal structure determination of the variant receptor A 2A AR[D52N] in complex with the full agonist UK432097 (PDB: 5WF5) showed that this structure is nearly identical to that of the A 2A AR complex with the same agonist (PDB: 3QAK) (Xu et al., 2011) , including nearly identical conformations of the intracellular signaling surfaces. In this paper, we further explore the structural basis of the Asp52 2.50 -related allosteric effects on the receptor function, showing that NMR in solution can provide novel insights. Based on sequence-specific assignment of numerous amino acid residues distributed throughout the receptor ( Figures 1C and S1 ), we report observations of a strong interplay between Asp52 2.50 and the ''toggle switch'' tryptophan at position 246 6.48 (Rosenbaum et al., 2009; Schwartz et al., 2006; Shi et al., 2002) , and of local structural polymorphisms on the A 2A AR intracellular surface which can be directly related to the functionality of the Asp52 2.50 allosteric switch.
RESULTS
We obtained sequence-specific resonance assignments for well-resolved resonances in the NMR spectra of A 2A AR (Figure 1D Figure 1F ). The assigned signals provided NMR probes of conformation in the hydrophobic core, at the extracellular surface with the entry to the orthosteric ligand binding cavity and at the intracellular surface ( Figure 1C ). The labeling also included helix VI, which has been observed in crystal structures to undergo a large structural rearrangement, relative to an antagonist complex, upon formation of a complex with an agonist (Xu et al., 2011) and in a ternary complex with an agonist and a G protein or G protein mimetic (Carpenter et al., 2016) . We then investigated the response of the assigned NMR signals to variable efficacy of bound drugs. To obtain information on the allosteric switch at Asp52 2.50 , we compared corresponding NMR data of A 2A AR and A 2A AR[D52N] , where the allosteric center is known to be inactive (Massink et al., 2015) . This experimental approach was based on the use of a novel expression system for GPCRs, which allowed us to obtain sequence-specific NMR assignments by single-residue amino acid replacements. N. The use of extensive deuteration provided the expected improvement of the A 2A AR NMR spectra ( Figure S2 ), which made the present project feasible. Optimization of each step of the expression and purification process resulted in the capability to routinely produce milligram-per-liter quantities of homogeneous isotopelabeled A 2A AR (see STAR Methods). A 2A AR reconstituted into LMNG/CHS mixed micelles for NMR studies was highly homogeneous, as observed by analytical SEC, which showed that samples were monodisperse and did not contain detectable amounts of aggregated protein ( Figure S3B ).
To ensure that the present solution NMR studies were performed with A 2A AR that was pharmacologically and structurally identical to A 2A AR produced in the widely used Sf9 cells (Carpenter et al., 2016; Jaakola et al., 2008; Xu et al., 2011) , we performed extensive characterization of A 2A AR produced from Pichia. Ligand binding experiments performed with A 2A AR that was either embedded in membranes isolated from Pichia preparations ( Figures S3C and S3D ) or reconstituted in LMNG/CHS micelles ( Figure S3A ) showed nearly identical activity to A 2A AR produced in Sf9 cells. A crystal structure of Pichia-produced A 2A AR in complex with the antagonist ZM241385 was found to be identical to an earlier corresponding structure of A 2A AR produced in Sf9 (Figures S3E and S3F ). (Table S1 ) (Johnson and Bovey, 1958; Koradi et al., 1996; Liu and Wü thrich, 2016; MacDonald and Phillips, 1967; Perkins and Wü thrich, 1979; Wü thrich, 1969 Wü thrich, , 1986 (Markley et al., 1968) and it became mandatory with the introduction of transverse relaxationoptimized spectroscopy (TROSY) for studies of large structures (Pervushin et al., 1997 (Figures 1 and 2 ), we could not establish whether or not the TROSY spectrum of Figure 1D includes signals from all residues in the polypeptide chain. In this situation, we selected 30 well-resolved polypeptide backbone signals, which all represent large conformation-dependent 1 H chemical shifts and are therefore sensitive probes of conformational rearrangements (Wü thrich, 1986) , to monitor the preservation of the overall three-dimensional fold in the variant A 2A ARs used for the NMR assignments (Figures S4, S5, and S6; Table S2 ). Table S1 .
studies predicted large changes in the rotamer state of Trp246 6.48 between GPCR complexes with agonists and antagonists (Nygaard et al., 2013; Shi et al., 2002) . Trp246 6.48 is located in helix VI at the bottom of the ligand-binding cavity ( Figure 1 ). Variations in the conformation of Trp 6.48 between antagonist and agonist complexes have been widely observed in crystal structures of class A human GPCRs (Rosenbaum et al., 2009) , including A 2A AR (Jaakola et al., 2008; Xu et al., 2011) and very recently, the human CB1 receptor (Hua et al., 2017 3A ). This ring current-shifted signal outside of the characteristic Trp indole 15 N-1 H spectral region can be expected to be highly sensitive to local conformational rearrangements, because these may cause large chemical shift changes (Johnson and Bovey, 1958; MacDonald and Phillips, 1967; Wü thrich, 1969 Wü thrich, , 1986 . The NMR signal of Trp246 6.48 in A 2A AR complexes with agonists was therefore de novo identified by amino acid replacement ( Figure 3B ), revealing a large chemical shift change relative to complexes with antagonists ( Figure 3A ). Table S1 shows that the observed chemical shift change is in good qualitative agreement with the difference between the ring current shifts calculated from the crystal structures. Within the expected accuracy of ring current shift analyses (Perkins and Wü thrich, 1979; Wü thrich, 1986) , this observation established direct correlations for conformational changes near Trp246 6.48 between inactive and active-like states of A 2A AR seen in solution and in crystal structures ( Figure 4A ). These structures were used to calculate the ring current shifts in Table S1 . Figures 3C and 3D ). Response to variable efficacy of bound drugs is thus preserved in A 2A AR[D52N] , where the allosteric switch is known to be inactivated (Massink et al., 2015) .
Considering the close proximity of Asp52 2.50 to the orthosteric ligand binding site ( Figure 1C to bound drugs with similar efficacy but different chemical structures ( Figure 3E ). Closely similar chemical shift differences were observed between complexes with different combinations of agonists and antagonists ( Figure S7 ), indicating that the observed NMR spectral changes were indeed a response to different drug efficacies, rather than being due to direct contacts with the different ligand chemical structures ( Figure 3E) . Overall, the data in Figure 3 Figure 3E ) for which crystal structures are available (Carpenter et al., 2016; Doré et al., 2011; Jaakola et al., 2008; Lebon et al., 2011; Xu et al., 2011) . Figure 4D  affords Details of the response to variable drug efficacy indicated in Figure 4D are shown in Figures 4E-4K Figure 6B ). In the A 2A AR[D52N]-agonist complex, Gly218 also showed increased NMR signal intensity compared to the same A 2A AR complex ( Figure 6C Figure 6E ). As an illustration of the inert behavior of residues near the extracellular surface ( Figure 6A ), Figures 6D and 6E show that Trp143 has the same chemical shift and signal intensity in spectra of A 2A AR and A 2A AR[D52N] for both agonist and antagonist complexes.
DISCUSSION
The result visualized in Figure 6A is highly intriguing in the context of literature data on allosteric coupling from G protein binding toward the drug binding sites in human GPCRs. Thus, studies of b 2 AR led to the conclusion that complex formation with an intracellular partner protein allosterically modulated the conformation of the orthosteric drug binding cavity at the extracellular receptor surface (DeVree et al., 2016; Staus et al., 2016) . Analogous observations were based on NMR spectroscopic studies of the b 1 -adrenergic receptor (b 1 AR) (Isogai et al., 2016) . In the present study, inactivation of the allosteric center changes the conformational dynamics on the intracellular surface and does not affect the conformation or dynamics of the extracellular receptor surface (Figure 6 ). This suggests that the view of GPCRs consisting of two semi-independent subdomains, an orthosteric domain that reacts to varied molecular ''triggers'' and an intracellular domain where signaling pathways converge Venkatakrishnan et al., 2016) , may also apply to A 2A AR, where the allosteric center links together the two regions through residue Asp 2.50 .
In A 2A AR, as previously observed for other GPCRs (Eddy et al., 2016; Horst et al., 2013; Kim et al., 2013; Kofuku et al., 2014; Liu et al., 2012a; Manglik et al., 2015; Nygaard et al., 2013; Okude et al., 2015; Sounier et al., 2015) , observations of local conformational polymorphisms by NMR spectroscopy in solution complement the available A 2A AR crystal structures (Carpenter et al., 2016; Cheng et al., 2017; Doré et al., 2011; Jaakola et al., 2008; Lebon et al., 2011; Segala et al., 2016; Sun et al., 2017; Xu et al., 2011) the same agonist showed no structural differences at the intracellular surface, even though the two proteins demonstrated striking differences in G protein signaling. Thus, the presently discovered relations between the presence of local polymorphisms at the intracellular tips of helices I and VI and signaling at the intracellular surface (Figure 7) to structural rearrangements of helices associated with receptor activation Rasmussen et al., 2011; Schwartz et al., 2006; Wacker et al., 2013 (Crocker et al., 2006) , which is coupled with an outward reorientation of the intracellular end of helix VI as part of a proposed two-step activation mechanism (Kimata et al., 2016) . Trp 6.48 has also been implicated in studies of so called ''efficacy switches'' whereby a single point mutation can modulate the efficacy of a bound ligand. In the chemokine receptor CCR5, the amino acid replacement G286 7.42 F converted some antagonists into full agonists (Steen et al., 2013) . Based on molecular modeling, a proposed mechanism for this effect involved reorientation of Trp 6.48 (Steen et al., 2013) . In the d-opioid receptor (DOR), an efficacy switch was observed for the variant D 2.50 N, which converted some antagonists into biased agonists The current study provides a means for assessing the extent to which concepts of GPCR ''microswitches'' and ''microdomains,'' first described in early literature of rhodopsin photoactivation, can be extended to other class A receptors. GPCR microswitches are local clusters of highly conserved amino acids proximately located in the receptor, which undergo coordinated structural changes between inactive and active states. The concept of microswitches or ''functional microdomains'' emerged from earlier studies that applied optical spectroscopy and site-directed mutagenesis to delineate contributions of specific amino acids to rhodopsin photoactivation Franke et al., 1990; Lin and Sakmar, 1996; Sakmar and Fahmy, 1995) . Of particular relevance to the current study is literature data that reported changes in UV-absorbance of tryptophan residues upon rhodopsin photoactivation (Lin and Sakmar, 1996) . Trp126 3.41 and Trp265 6.48 in rhodopsin were observed to transition from more hydrophobic to more hydrophilic environments upon activation; in particular, Trp265 6.48 experienced the largest change in local environment among all the rhodopsin tryptophans (Lin and Sakmar, 1996) . Additional literature data correlated changes in interactions among rhodopsin transmembrane residues with varied functional responses (Beck et al., 1998; Han et al., 1998; Shieh et al., 1997) , giving rise to the idea of ''functional microdomains'' (Lin et al., 2000) . The present study corroborates the main ideas of functional microswitches and microdomains in A 2A AR and provides a more solid structural foundation with tools that were not available at the time of these earlier rhodopsin studies.
The observations presented in this study were made possible by a multi-parameter NMR characterization of the conformation and dynamics of a human GPCR in solution. Most earlier NMR studies of human GPCRs have utilized a smaller number of reporter groups introduced by chemical conjugation after protein production, including 19 F-NMR probes introduced by labeling of surface-exposed cysteine residues (Chung et al., 2012; Horst et al., 2013; Kim et al., 2013; Klein-Seetharaman et al., 1999; Liu et al., 2012a; Manglik et al., 2015) , and 13 CH 3 -probes introduced by reductive methylation of lysine residues (Bokoch et al., 2010; (Massink et al., 2015) ; the broken arrow indicates that an NMR-detectable structural response to variable efficacy of the bound drug was observed. The connection between the toggle switch Trp246 6.48 and the allosteric switch at Asp52 2.50 is supported by the observation of a strong interplay between these two centers in the present work. Kofuku et al., 2012 Kofuku et al., , 2014 Nygaard et al., 2013; Okude et al., 2015; Sounier et al., 2015) . While these have been highly successful in providing information at targeted locations, the stable-isotope-labeling strategy used here provides a more comprehensive view of GPCR activation. For future studies, this approach provides an avenue for obtaining ever denser networks of assigned NMR signals for monitoring functionrelated conformational rearrangements in GPCRs at ever higher resolution.
With regard to the physiological relevance, it is of key importance that the present study used a construct of the human A 2A AR that was closely similar to the native receptor, i.e., it did not contain either thermostabilizing point mutations or fusion proteins inserted into receptor loops, as is extensively used to make GPCRs amenable for crystallographic studies and also applied to other experimental techniques. Eliminating thermostabilizing modifications enables one to obtain information of the global dynamics and plasticity of GPCRs. Thus, the present study provides a framework whereby dynamic processes at the intracellular surface can be observed in parallel to monitoring structural changes in other regions of the receptor.
STAR+METHODS
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Protein Expression
For production of A 2A AR for NMR studies, the gene encoding human A 2A AR(1-316) containing a point mutation to remove the only glycosylation site (N154Q), an N-terminal FLAG tag, and a 10 X C-terminal His tag was cloned into a pPIC9K vector (Invitrogen) at the BamHI and NotI restriction sites. The pharmacological response of this construct to binding of orthosteric ligands has been demonstrated to be unchanged from the WT sequence (Palmer and Stiles, 1997) . We expressed all A 2A AR NMR samples in Pichia pastoris and demonstrated that the protein was functionally and structurally identical to A 2A AR expressed in insect cells by validating the pharmacological response of A 2A AR to orthosteric ligands and by crystal structure comparison of the antagonist ZM241385 complexes of A 2A AR expressed, respectively, in Sf9 (PDB 4EIY) and in P. pastoris (PDB 6AQF), both with the protein BRIL fused into ICL3 ( Figure S3 ). The construct was introduced by electroporation into the BG12 strain of Pichia pastoris (Biogrammatics, Carlsbad, CA).
For production of A 2A AR for crystal structure determination, the employed construct was nearly identical to a previously published construct (Chun et al., 2012; Liu et al., 2012b) which contained a fusion with residues 1 to 106 of apo-cytochrome b 562 RIL, in the place of the residues 209 to 218 in the ICL3, and was thermostabilized by the amino acid replacements M7W, H102I and K106L. The only differences to this earlier construct were the removal of an N-terminal HA leader sequence and the amino acid exchange N154Q.
Expression was screened by small-scale protein production and Western Blots, i.e., about fifteen clones per construct were grown in 4 mL cultures and protein production was assessed by anti-FLAG Western Blots. From these clones, the highest expressing clone was selected for future experiments. Glycerol stocks of the high expressing clone were used to inoculate a 5 mL starter culture in buffered minimal glycerol (BMGY) media, which was grown at 30 C to an O.D. of 7-10 in a 15 mL culture tube. Cells were collected by centrifugation at 3000 x g for 10 minutes and used to inoculate 50 mL BMGY medium in a 250 mL baffled flask, which was grown at 30 C to an O.D. of 15-20. This entire culture was then used to inoculate 500 mL BMGY media and allowed to grow at 30 C to reach an O.D. of 15-20. Cells were collected by centrifugation at 3000 x g for 15 minutes and resuspended in buffered minimal methanol (BMMY) medium without methanol and the temperature was lowered to 27 C. The cultures were allowed to shake for 3-4 hours to ensure complete metabolisation of glycerol before methanol was added to a final concentration of 0.5% w/v to induce protein expression. Two additional 0.5% w/v aliquots of methanol were added 12 and 24 hours after induction. Expression proceeded for a total of 36 hours until cells were harvested by centrifugation at 3500 x g for 15 minutes. The isolated cell pellets were frozen in liquid nitrogen and stored at À80 C for future processing. (Caffrey and Cherezov, 2009 ). Diffraction quality crystals were obtained with the same conditions as used for the crystallization of Sf9-produced A 2A AR-BRIL (Chun et al., 2012; Liu et al., 2012b) . X-ray diffraction data were collected on the 23ID-D beamline (GM/CA CAT) at the Advanced Photon Source, Argonne, IL using a Pilatus3 6M detector (X-ray wavelength 1.033 Å ). The crystals were exposed with a 10 mm mini-beam for 1 s and 1.0 oscillation per frame. HKL2000 (Otwinowski and Minor, 1997) was used for integrating, scaling and merging data from 18 best-diffracting crystals of the A 2A AR-BRIL from Pichia pastoris in complex with ZM241385.
Initial phase information of A 2A AR-BRIL from Pichia pastoris was obtained by molecular replacement (MR) with PHASER (McCoy et al., 2007) using A 2A AR-BRIL (PDB: 4EIY) as a search model. Refinement was performed with REFMAC5 (Murshudov et al., 1997; Otwinowski and Minor, 1997) and autoBUSTER (Bricogne et al., 2016) followed by manual examination and rebuilding of the refined coordinates in the program COOT (Emsley and Cowtan, 2004) , using both j2F o j-jF c j and jF o j -jF c j maps. TLS refinement strategy with two TLS groups (GPCR and BRIL domains) was incorporated in the refinement.
The final model of the A 2A AR-BRIL complex contains residues À2 to 1 from the expression tag, 2-208, 219-306 of A 2A AR, 1001-1042 and 1058-1106 of BRIL, and the ligand ZM241385 (ZMA as defined in the coordinate file), 3 cholesterols, 7 oleic acids, 5 OLC (or OLB), and 19 waters. The remaining C-terminal residues beyond 306 were disordered and not visible in the electron density maps and were therefore not modeled. The final model has good stereochemistry with no Ramachandran outliers (99.0% in favored and 1.0% in allowed regions), as determined by Molprobity . Data collection and refinement statistics are summarized in Table S3 .
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification and analysis of ligand binding for A 2A AR in Pichia membranes Binding parameters were calculated using Prism 6 software (GraphPad). IC 50 values obtained from displacement curves were converted to K i values using the Cheng-Prusoff equation (Cheng and Prusoff, 1973) . All data are expressed as the mean ± standard error from three independent experiments performed in triplicate.
Quantification of ligand binding for A 2A AR in LMNG/CHS performed by the scintillation proximity assay The data were analyzed by Prism 6.05 (GraphPad) to give K D and K i values and reported as the mean ± SD and done three times or more in triplicate.
DATA AND SOFTWARE AVAILABILITY
The accession number for the NMR assignments reported in this paper is Biological Magnetic Resonance Data Bank (BMRB): 27328. The accession number for the structure of A 2A AR-BRIL in complex with ZM241385 expressed in P. pastoris reported in this paper is Protein Data Bank (PDB): 6AQF.
